Table 4.
Virus sensitivity to NA inhibitors in vitro a
| Virus | NA change | IC50 values (nM) of NA inhibitors (fold differencesb) | |||
|---|---|---|---|---|---|
| Oseltamivir carboxylatec | Zanamivir | Peramivir | Laninamivird | ||
| rPhuket3073/Yamagatae | wild‐type | 64.9 ± 11.7 (1.0) | 5.9 ± 1.1 (1.0) | 0.5 ± 0.1 (1.0) | 2.5 ± 0.1 (1.0) |
| rPhuket3073/Yamagata‐E117Af | E117A | 38 075.9 ± 7365.0 (586.6) | 164 197.3 ± 29 976.2 (27 830.0) | 14 959.5 ± 296.9 (29 919.0) | 54 022.7 ± 4659.7 (21 609.1) |
| B/Tokyo/UT‐AC032/2018 | G407S | 537.2 ± 215.7 (8.3) | 986.6 ± 507.9 (167.2) | 32.1 ± 12.9 (64.2) | 510.1 ± 244.4 (204.0) |
a
IC50 values were determined by using an NA‐Fluor Influenza Neuraminidase Assay Kit. Average IC50 values and standard deviations were calculated from three independent assays performed in duplicate.
b
Compared with IC50 values obtained with the sensitive control rPhuket3073/Yamagata.
c
Oseltamivir carboxylate is the active form of oseltamivir.
d
Laninamivir is the active form of laninamivir octanoate.
e
A recombinant virus possessing the HA and NA genes from B/Phuket/3073/2013 and the remaining genes from B/Yamagata/1/73 virus.
f
A recombinant Phuket3073/Yamagata virus with an E117A mutation in its NA.